Sugi Predict

Sugi Predict / Compounds / SCHEMBL17569730

SCHEMBL17569730

SCHEMBL17569730

c1ccc(-c2cnc3[nH]nc(-c4nc5c(-c6ccccn6)nccc5[nH]4)c3c2)nc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 12/20 0.60
▸ CLK2 P49760 11/20 0.60
▸ CLK3 P49761 11/20 0.60
▸ WNT1 P04628 6/20 0.49
▸ TGFBR1 P36897 4/20 0.49
▸ ULK1 O75385 1/20 0.49
▸ CDK7 P50613 1/20 0.49
▸ CDK5 Q00535 1/20 0.49
▸ PRKCE Q02156 1/20 0.49
▸ CAMK2G Q13555 1/20 0.49
▸ CDK5R1 Q15078 1/20 0.49
▸ RPS6KA1 Q15418 1/20 0.49
▸ AAK1 Q2M2I8 1/20 0.49
▸ MAP3K19 Q56UN5 1/20 0.49
▸ CAMKK1 Q8N5S9 1/20 0.49
▸ CAMKK2 Q96RR4 1/20 0.49
▸ CHEK1 O14757 1/20 0.43
▸ PIM1 P11309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17569742 0.93 CLK2 (0.58) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569717 0.92 DYRK1A (0.55) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569739 0.92 DYRK1A (0.59) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569046 0.91 DYRK1A (0.61) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569729 0.90 DYRK1A (0.57) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569028 0.90 DYRK1A (0.60) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569675 0.90 DYRK1A (0.53) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569704 0.90 DYRK1A (0.65) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17555810 0.89 WNT1 (0.60) DYRK1ACLK2CLK3WNT1TGFBR1
SCHEMBL17569833 0.89 CLK2 (0.54) DYRK1ACLK2CLK3WNT1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US claimed
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-11-15 — — US claimed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US claimed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US claimed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US claimed
WO-2016040193-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO claimed
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885CLK3 2155/4885
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885CLK3 2155/4885
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885CLK3 2155/4885
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885CLK3 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.